Cargando…

Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?

Detalles Bibliográficos
Autores principales:	Yu, Yao, Zakeri, Kaveh, Lee, Nancy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522846/ https://www.ncbi.nlm.nih.gov/pubmed/34676054 http://dx.doi.org/10.18632/oncotarget.27987

Ejemplares similares

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
por: Kumaraswamy, Santosh
Publicado: (2021)

Peer Review of Head and Neck Cancer Planning Target Volumes in Radiation Oncology
por: Hesse, Jennifer, et al.
Publicado: (2022)

Combinations of immunotherapy and radiation therapy in head and neck squamous cell carcinoma: a narrative review
por: Hayman, Thomas J., et al.
Publicado: (2021)

Correlation of an Electronic Geriatric Assessment With Receipt of Adjuvant Radiation and Chemotherapy in Older Adults With Head and Neck Cancer
por: Restifo, Daniel, et al.
Publicado: (2022)

Mask‐related anxiety and distress during radiation therapy for head and neck cancer
por: Dhillon, Haryana M., et al.
Publicado: (2023)

The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer
por: Atiq, Saad O., et al.
Publicado: (2018)

The immunogenic radiation and new players in immunotherapy and targeted therapy for head and neck cancer
por: Sharon, Shay, et al.
Publicado: (2023)

Combining Radiotherapy and Immunotherapy in Head and Neck Cancer
por: Runnels, Juliana, et al.
Publicado: (2023)

Covid-19 pandemic and head and neck cancers, what should we expect?
por: Pucci, Resi, et al.
Publicado: (2021)

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
por: Guigay, Joël, et al.
Publicado: (2021)

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab
por: Terranova, Nadia, et al.
Publicado: (2022)

Speech therapy in head and neck cancer
por: Rossi, Vaneli Colombo, et al.
Publicado: (2021)

Can the Risk of Dysphagia in Head and Neck Radiation Therapy Be Predicted by an Automated Transit Fluence Monitoring Process During Treatment? A First Comparative Study of Patient Reported Quality of Life and the Fluence-Based Decision Support Metric
por: Lim, Seng Boh, et al.
Publicado: (2021)

Should We Be Permissive with Hypercapnia?
por: Nassar, Boulos
Publicado: (2022)

What Should We Eat?
Publicado: (1909)

Radiation therapy in head and neck cancer
por: Alfouzan, Afnan F.
Publicado: (2021)

Recent Research on Combination of Radiotherapy with Targeted Therapy or Immunotherapy in Head and Neck Squamous Cell Carcinoma: A Review for Radiation Oncologists
por: Xing, Daniel Tao, et al.
Publicado: (2021)

Second-line avelumab in platinum-treated non-small cell lung cancer patients: comment on the JAVELIN Lung 200 clinical trial
por: Rocco, Danilo, et al.
Publicado: (2019)

Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions
por: Won, Ho-Ryun, et al.
Publicado: (2021)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

A RESPONSIBILITY THAT WE SHOULD NOT SHIRK
por: Kuruvilla, K.
Publicado: (1995)

Should we SUSPEND MET? Not really
por: Sairam, Krishnamurthy
Publicado: (2016)

Should we hunt a metric?
por: Villar, Richard (Ricky)
Publicado: (2019)

Why should we continue to learn?
por: Golnik, Karl
Publicado: (2017)

Should we open the reviewing process
por: Mrša, Vladimir
Publicado: (2021)

CUREs in biochemistry—where we are and where we should go
por: Bell, Jessica K., et al.
Publicado: (2016)

Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors
por: Darragh, Laurel B., et al.
Publicado: (2022)

Radiation Therapy in the Treatment of Head and Neck Rhabdomyosarcoma
por: Frankart, Andrew J., et al.
Publicado: (2021)

Overcoming Resistance to Immunotherapy in Head and Neck Cancer Using Radiation: A Review
por: Hui, Caressa, et al.
Publicado: (2021)

Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it?
por: Merlano, Marco C, et al.
Publicado: (2018)

Neoantigen evolution in head and neck cancer progression: where do we go from here?
por: Rosenberg, Ari Joseph, et al.
Publicado: (2021)

Molecular Diagnosis in 100% of Dystrophinopathies: Are We There Yet?
por: Pegoraro, Elena
Publicado: (2021)

Respondent driven sampling—where we are and where should we be going?
por: White, Richard G, et al.
Publicado: (2012)

Should we, can we, halt the rise in prescribing for pain and distress?
por: Byng, Richard
Publicado: (2020)

COVID-19 Vaccination. Where Are We and Where Should We Go?
por: Peña-Otero, David
Publicado: (2022)

The Evolving Role of Stereotactic Body Radiation Therapy for Head and Neck Cancer: Where Do We Stand?
por: Mohamad, Issa, et al.
Publicado: (2023)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

Men's Health: What Should We Know?
por: Kim, Sae Woong
Publicado: (2015)

We should avoid the term “fluid overload”
por: Vincent, Jean-Louis, et al.
Publicado: (2018)

Should We Tip Our CAPs to Statins?
por: Simpson, A. John, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qvso6f3ji6o3brr71tkmihc7e3